RT Journal Article
SR Electronic
T1 Neutralizing antibody response in non-hospitalized SARS-CoV-2 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.07.20169961
DO 10.1101/2020.08.07.20169961
A1 Natalia Ruetalo
A1 Ramona Businger
A1 Karina Althaus
A1 Simon Fink
A1 Felix Ruoff
A1 Klaus Hamprecht
A1 Bertram Flehmig
A1 Tamam Bakchoul
A1 Markus F. Templin
A1 Michael Schindler
YR 2020
UL http://medrxiv.org/content/early/2020/08/07/2020.08.07.20169961.abstract
AB The majority of infections with SARS-CoV-2 (SCoV2) are asymptomatic or mild without the necessity of hospitalization. It is of outmost importance to reveal if these patients develop an antibody response against SCoV2 and to define which antibodies confer virus neutralization. We hence conducted a comprehensive serological survey of 49 patients with a mild course of disease and quantified neutralizing antibody responses against authentic SCoV2 employing human cells as targets.Four patients (8%), even though symptomatic, did not develop antibodies against SCoV2 and two other sera (4%) were only positive in one of the serological assays employed. For the remainder, antibody response against the S-protein correlated with serum neutralization whereas antibodies against the nucleocapsid were poor predictors of virus neutralization. Only six sera (12%) could be classified as highly neutralizing. Furthermore, sera from several individuals with fairly high antibody levels had only poor neutralizing activity. In addition, our data suggest that antibodies against the seasonal coronavirus 229E contribute to SCoV2 neutralization.Altogether, we show that there is a wide breadth of antibody responses against SCoV2 in patients that differentially correlate with virus neutralization. This highlights the difficulty to define reliable surrogate markers for immunity against SCoV2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants to MS from the Baden-Wuerttemberg foundation (BW-Stiftung), the Deutsche Forschungsgemeinschaft as well as by basic funding provided to MS by the University Hospital Tuebingen and TUFF-Gleichstellungsfoerderung to K.A. (2563-0-0).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We obtained IRB approval from the local ethics committees #222/2020BOAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data is within the manuscript and the supplementary information file.